PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Quotient Bioresearch to Showcase its Leading-edge Technologies and Services at 2009 AAPS - Quotient Bioresearch to showcase its leading-edge technologies and services at 2009 AAPS Annual Meeting and Exposition
Quotient Bioresearch to Showcase its Leading-edge Technologies and Services at 2009 AAPS

 

NewswireToday - /newswire/ - Cambridgeshire, United Kingdom, 2009/10/14 - Quotient Bioresearch to showcase its leading-edge technologies and services at 2009 AAPS Annual Meeting and Exposition.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Quotient Bioresearch ("Quotient"), a leading provider of early drug development services, will be showcasing the breadth of its leading-edge technologies and services for early drug development at the American Association of Pharmaceutical Scientists (AAPS) 2009 Annual Meeting and Exposition, on booth #2446.

Quotient is uniquely placed to offer its clients significant benefits (shorter time lines, reduced complexity and lower costs) and will highlight its recently launched 14C Synthesis-to-Clinic service and its unique Translational Pharmaceutics platform:

(i) 14C Synthesis-to-Clinic - as a world leader in 14C enabled drug development (including custom synthesis, metabolism, microdosing, and microtracer studies), Quotient's integrated Synthesis-to-Clinic service simplifies the procurement of Regulatory and non-Regulatory 14C studies in support of the drug development needs of our clients.

(ii) Translational Pharmaceutics - Quotient has pioneered the development of an integrated formulation development, drug product manufacturing and clinical testing platform, which increases the efficiency and precision with which an optimised oral drug product can be identified for further development and results in significantly reduced development timelines and associated cost savings.

The range of drug development services offered by Quotient also includes:

• 14C Custom Synthesis- manufacture of custom 14C radio-labelled drug compounds (final products and intermediates);
• Pre-clinical Metabolism - offering a full range of in vivo and in vitro metabolism studies covering all FDA guidelines;
• Early Clinical - First-in-Human through to Proof of Concept;
• Bioanalytical Sciences - spanning small molecules, biopharmaceuticals, biomarkers, clinical laboratory support and microbiology.

Quotient's Chairman and Chief Executive Paul Cowan commented "We can support our clients with a unique offering of technologies and services for all stages of early drug development. AAPS is a leading event for pharmaceutical scientists working in clinical science and provides Quotient with an excellent opportunity to meet with existing and potential clients from around the world to demonstrate the breadth of solutions we can offer them for their early drug development needs."

Quotient's full service offering will be featured on booth #2446 at AAPS 2009 and other events at the congress including:

• Nine poster presentations covering a range of early development case studies.
• An open forum session entitled "An evolution or revolution in drug metabolism" on Thursday 12th November 2009 at 1.30 - 5.00pm.
• A social/networking evening on Monday 9th November 2009 for over 200 of our most valued clients and collaborators.

To learn more about Quotient's service offering, please visit booth #2446 at AAPS 2009.

About Quotient Bioresearch
Quotient (quotientbioresearch.com) is a leading provider of drug development services with a focus on early-stage drug development services. The Company offers a unique range of drug development services through its three principal operating units - Quotient Chemistry & Metabolism, Quotient Bioanalytical Sciences and Quotient Clinical. Quotient has grown rapidly in the past three years, through a combination of both acquisition-led and organic growth. Quotient Bioresearch is part of Quotient Bioscience Group, which comprises Quotient Bioresearch, HFL Sport Science and Quotient Biodiagnostics.

For further press information please contact: Sarah Evans - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. T: +44 1477 539 539; F: +44 1477 539 540; E: quotient[.]scottpr.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Quotient Bioresearch to Showcase its Leading-edge Technologies and Services at 2009 AAPS

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sarah Evans 
+44 (0)1638 720 500 info[.]quotientbioresearch.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)